Fulcrum Therapeutics, Inc. (FULC) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Fulcrum Therapeutics, Inc. (FULC) closed at USD 3.67 on 2026-10-14, a change of -63.3 % over the past year, with a market capitalization of USD 280.32M.

Fulcrum Therapeutics, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Fulcrum Therapeutics, Inc. key figures

Previous close

USD 3.67 (2026-10-14)

1-year change

-63.3 %

Market cap

USD 280.32M

Enterprise value

USD -33.55M

P/E ratio (trailing)

-3.03

P/E ratio (forward)

-6.70

EPS (trailing)

-1.21

EPS (forward)

-0.55

PEG ratio

n/a

Price to book

0.90

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

4.90

Employees

9

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Fulcrum Therapeutics, Inc.

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia. The company also discovers programs for the treatment of diamond-blackfan anemia, Bone Marrow Failure Syndromes, novel fetal hemoglobin inducers, fibrotic disorders. It has licensce agreement with CAMP4 which includes certain small molecule compounds, composition of matter and method of use patent rights, and know-how to research, develop, manufacture, use, and commercialize. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Fulcrum Therapeutics, Inc. and compare it with other stocks.